The Hidden Cost of Doing Nothing: Risks to Revenue and Patient Care if You Delay Prostate MRI-Fusion Adoption

The 2026 prostate biopsy CPT changes mark a clear shift away from ultrasound-only workflows and toward MRI-guided and MRI-fusion prostate biopsy techniques. With the deletion of the catch-all CPT® 55700 and the introduction of new prostate biopsy CPT codes, biopsy approaches are no longer grouped together under a single procedural definition. Imaging guidance and targeting now play a central role in how prostate biopsies are classified.

Many urology practices already recognize the clinical value of MRI-fusion biopsy. What has become clearer under the current CPT framework is that continued reliance on ultrasound-only, untargeted biopsies introduces new clinical and financial risk. Workflow choices that once fit comfortably within existing processes now face greater scrutiny as biopsy approaches are more explicitly differentiated.

Avoid Workflow Misalignment Under the New CPT Structure

When prostate biopsy workflows do not align with how procedures are now defined, practices face increased exposure to denied claims, inconsistent/lower reimbursement, and administrative rework. As prostate fusion biopsy CPT codes distinguish imaging-guided procedures from ultrasound-only approaches, legacy workflows may no longer map cleanly to documentation and billing requirements.

Also, performing only untargeted biopsies carries downstream implications besides lower reimbursement. Lower high-grade cancer detection can lead to repeat procedures, delayed treatment, patient dissatisfaction and expanded follow-up, increasing the overall burden on staff and resources. Fragmented pathways, where imaging and biopsy occur at locations outside the office, add further complexity, scheduling and coordination demands. In addition, physician biopsy reimbursement for fusion at hospitals and ASCs is much lower than reimbursement in the office. Over time, these inefficiencies contribute to lost revenue and greater operational strain.

Closing Diagnostic Gaps with Targeted, MRI-Fusion Biopsy Procedures

Clinical evidence underscores why these differences matter. In a large randomized trial, MRI-targeted biopsy pathways reduced unnecessary biopsies while improving detection of clinically significant prostate cancer, highlighting inefficiencies associated with untargeted approaches.¹ Other studies evaluating MRI-based fusion biopsy have also demonstrated improved detection rates, including in patients with normal digital rectal examinations, reinforcing known diagnostic limitations of untargeted biopsies.²

As reimbursement models now reflect these distinctions and support AUA clinical guideline recommendations for MRI-guidance on all prostate biopsies, the financial and clinical impact of maintaining ultrasound-only workflows becomes harder to ignore.

For practices, MRI-guided biopsy also supports more integrated procedural workflows. UC-CARE’s Navigo 4D fusion navigation system is designed to support MRI-guided prostate biopsy in the office by automatically compensating for patient motion and following your ultrasound settings changes in real time, and automatically marking every biopsy for optimized patient treatment planning and reimbursement documentation.

UC-CARE’s companion Fusion Studio tool supports image preparation and planning, allowing cases to move from imaging to procedure within a single system. Navigo Fusion Studio’s automated algorithms allow radiologists to quickly prepare images to be processed by Navigo. Cases can be automatically sent to the Navigo workstation, streamlining the process from planning to procedure.

By enabling accurate targeting and streamlined workflow integration, MRI-fusion biopsy helps practices align clinical performance with how prostate biopsy procedures are now differentiated. The result is a biopsy program that supports improved patient care while reducing reliance on workflows that no longer reflect current standards.

A Clear Path to MRI-Fusion Adoption

The current prostate biopsy CPT framework reflects a shift already underway in clinical practice. MRI-fusion prostate biopsy techniques are now clearly favored over ultrasound-only approaches in how procedures are defined and evaluated. Continued reliance on ultrasound-only, untargeted biopsies increases exposure to lower reimbursement, and diagnostic gaps that affect patient care.

Aligning biopsy programs with MRI-guided approaches is now essential for maintaining a sustainable, future-ready biopsy practice, and Navigo 4D Fusion offers affordable pay-per-procedure options that can easily fit into any budget.

With the right planning, practices can reduce uncertainty, support accurate diagnosis, and move forward with confidence under today’s biopsy framework.

A consultation with UC-CARE is the fastest way for urology practices to assess MRI-fusion biopsy workflows and learn how Navigo aligns procedures with current prostate biopsy CPT codes. Get in touch to schedule your consultation today!

---

Sources

1. Kasivisvanathan, Veeru, Ari S. Rannikko, Marco Borghi, et al. “MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.” New England Journal of Medicine 378, no. 19 (2018): 1767–1777. https://doi.org/10.1056/NEJMoa1801993.

2. Nativ, Omri, Eyal Zisman, Doron Zisman, et al. “The Additive Value of mpMRI on Prostate Cancer Detection: Comparison between Patients with and without a Suspicious Digital Rectal Examination.” Urologic Oncology: Seminars and Original Investigations 38, no. 3 (2020): 1–5.